ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effects of Provent® on Obstructive Sleep Apnea During Continuous Positive Airway Pressure Therapy Withdrawal

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01332175
Recruitment Status : Completed
First Posted : April 8, 2011
Last Update Posted : August 16, 2012
Sponsor:
Information provided by (Responsible Party):
University of Zurich

Brief Summary:
Randomised, placebo-controlled trial of continuous positive airway pressure therapy (CPAP) versus Provent® and Placebo-Provent® to define the effects of Provent® on the severity of obstructive sleep apnea, daytime symptoms as well as on measures of cardiovascular risk.

Condition or disease Intervention/treatment Phase
Obstructive Sleep Apnea Device: Provent® Device: Placebo-Provent® Procedure: CPAP Not Applicable

Detailed Description:

Randomised, placebo-controlled trial of Provent® versus Placebo-Provent® versus continuous positive airway pressure therapy (CPAP) to define the effects of Provent® on the severity of obstructive sleep apnea, daytime symptoms as well as on measures of cardiovascular risk in patients with obstructive sleep apnea.

Patients successfully treated with CPAP will be randomised to one of three arms for a duration of 2 weeks:

  1. Withdraw CPAP and use Provent®
  2. Withdraw CPAP and use Placebo-Provent®
  3. Continue treatment with CPAP

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 67 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Effects of Provent® on Obstructive Sleep Apnea During Continuous Positive Airway Pressure Therapy Withdrawal: a Randomised Controlled Trial.
Study Start Date : April 2011
Actual Primary Completion Date : August 2012
Actual Study Completion Date : August 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sleep Apnea

Arm Intervention/treatment
Active Comparator: Provent Device: Provent®
Nightly use of Provent® versus Placebo-Provent® versus CPAP

Placebo Comparator: Placebo-Provent Device: Provent®
Nightly use of Provent® versus Placebo-Provent® versus CPAP

Device: Placebo-Provent®
Nightly use of Provent® versus Placebo-Provent® versus CPAP

Active Comparator: CPAP Device: Provent®
Nightly use of Provent® versus Placebo-Provent® versus CPAP

Procedure: CPAP
Nightly use of Provent® versus Placebo-Provent® versus CPAP




Primary Outcome Measures :
  1. Sleep apnoea severity, daytime symptoms of sleep apnoea [ Time Frame: 2 weeks ]

Secondary Outcome Measures :
  1. Blood pressure [ Time Frame: 2 weeks ]
    Comparison of changes in systolic and diastolic blood pressure from baseline to follow-up at 2 weeks.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Objectively confirmed obstructive sleep apnoea (at the time of original diagnosis) with an oxygen desaturation index (ODI, >4% dips) of between 10 and 50/h and an ESS of >10 (these thresholds will exclude subjects with borderline and very severe forms of OSA in whom there may be a disproportionate treatment effect).
  2. Currently >10/h oxygen desaturations (>4% dips) during an ambulatory nocturnal pulse oximetry performed at the end of a 4-night period without CPAP.
  3. Treated with NCPAP for more than 12 months, minimum compliance 4h per night.
  4. Current ESS < 10.
  5. Written informed consent.

Exclusion criteria:

  1. Previous ventilatory failure (awake resting arterial oxygen saturation <93% or arterial PCO2 > 6kPa).
  2. Unstable, untreated coronary or peripheral artery disease, severe arterial hypertension (>180/110mmHg).
  3. Previously diagnosed with Cheyne-Stokes breathing.
  4. Current professional driver.
  5. Any sleep related accident.
  6. Age <20 or >75 years at trial entry.
  7. History of chronic nasal obstruction.
  8. Mental or physical disability precluding informed consent or compliance with the protocol .
  9. Non-feasible trial follow-up (for example, distance from follow-up centre, physical inability).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01332175


Locations
Switzerland
Cantonal Hospital Munsterlingen, Departement of Internal Medicine, Pulmonary Division
Munsterlingen, Switzerland, 8596
University Hospital Zurich, Pulmonary Division
Zurich, Switzerland, 8091
United Kingdom
Churchill Hospital, Oxford Centre for Respiratory Medicine
Oxford, United Kingdom, OX3 7LJ
Sponsors and Collaborators
University of Zurich
Investigators
Principal Investigator: Malcolm Kohler, MD, Leading Physician University Hospital Zurich, Division of Pneumology

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT01332175     History of Changes
Other Study ID Numbers: EK-1600
First Posted: April 8, 2011    Key Record Dates
Last Update Posted: August 16, 2012
Last Verified: August 2012

Additional relevant MeSH terms:
Apnea
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases